Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nachbagauer

Showing results (81-90 of 102) with videos related to

Pageof 11
Sort By:
The Lancet. Infectious Diseases|September 8, 2024
Safety and immunogenicity of mRNA-based seasonal influenza vaccines formulated to include multiple A/H3N2 strains with or without the B/Yamagata strain in US adults aged 50-75 years: a phase 1/2, open-label, randomised trialDenise Hsu, Akila Jayaraman, Alicia Pucci, et al.
Human Vaccines & Immunotherapeutics|February 2, 2026
Phase 1/2 randomized, observer-blind clinical trial of a first-generation, mRNA-based vaccine against seasonal influenza and COVID-19 in healthy adultsAmanda K Rudman Spergel, Carole Henry, Raffael Nachbagauer, et al.
Science Translational Medicine|June 3, 2021
First exposure to the pandemic H1N1 virus induced broadly neutralizing antibodies targeting hemagglutinin head epitopesJenna J Guthmiller, Julianna Han, Lei Li, et al.
Biorxiv : the Preprint Server for Biology|October 17, 2024
mRNA-based influenza vaccine expands breadth of B cell response in humansHanover C Matz, Tae-Geun Yu, Julian Q Zhou, et al.
Vaccines|November 13, 2020
Development and Assessment of a Pooled Serum as Candidate Standard to Measure Influenza A Virus Group 1 Hemagglutinin Stalk-Reactive AntibodiesJuan Manuel Carreño, Jacqueline U McDonald, Tara Hurst, et al.
Nature Immunology|June 15, 2026
mRNA-based influenza vaccine expands the B cell response breadth in humansHanover C Matz, Tae-Geun Yu, Kritika Dixit, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 15, 2020
Adjuvanted H5N1 influenza vaccine enhances both cross-reactive memory B cell and strain-specific naive B cell responses in humansAli H Ellebedy, Raffael Nachbagauer, Katherine J L Jackson, et al.
Immunity|October 23, 2020
Polyreactive Broadly Neutralizing B cells Are Selected to Provide Defense against Pandemic Threat Influenza VirusesJenna J Guthmiller, Linda Yu-Ling Lan, Monica L Fernández-Quintero, et al.
Vaccine|January 5, 2025
Anti-neuraminidase and anti-hemagglutinin stalk responses to different influenza a(H7N9) vaccine regimensHana M El Sahly, Evan J Anderson, Lisa A Jackson, et al.
Science Translational Medicine|December 18, 2024
An influenza mRNA vaccine protects ferrets from lethal infection with highly pathogenic avian influenza A(H5N1) virusMasato Hatta, Yasuko Hatta, Angela Choi, et al.
Pageof 11

Showing results (81-90 of 102) with videos related to

Sort By:
Pageof 11
The Lancet. Infectious Diseases|September 8, 2024
Safety and immunogenicity of mRNA-based seasonal influenza vaccines formulated to include multiple A/H3N2 strains with or without the B/Yamagata strain in US adults aged 50-75 years: a phase 1/2, open-label, randomised trialDenise Hsu, Akila Jayaraman, Alicia Pucci, et al.
Human Vaccines & Immunotherapeutics|February 2, 2026
Phase 1/2 randomized, observer-blind clinical trial of a first-generation, mRNA-based vaccine against seasonal influenza and COVID-19 in healthy adultsAmanda K Rudman Spergel, Carole Henry, Raffael Nachbagauer, et al.
Science Translational Medicine|June 3, 2021
First exposure to the pandemic H1N1 virus induced broadly neutralizing antibodies targeting hemagglutinin head epitopesJenna J Guthmiller, Julianna Han, Lei Li, et al.
Biorxiv : the Preprint Server for Biology|October 17, 2024
mRNA-based influenza vaccine expands breadth of B cell response in humansHanover C Matz, Tae-Geun Yu, Julian Q Zhou, et al.
Vaccines|November 13, 2020
Development and Assessment of a Pooled Serum as Candidate Standard to Measure Influenza A Virus Group 1 Hemagglutinin Stalk-Reactive AntibodiesJuan Manuel Carreño, Jacqueline U McDonald, Tara Hurst, et al.
Nature Immunology|June 15, 2026
mRNA-based influenza vaccine expands the B cell response breadth in humansHanover C Matz, Tae-Geun Yu, Kritika Dixit, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 15, 2020
Adjuvanted H5N1 influenza vaccine enhances both cross-reactive memory B cell and strain-specific naive B cell responses in humansAli H Ellebedy, Raffael Nachbagauer, Katherine J L Jackson, et al.
Immunity|October 23, 2020
Polyreactive Broadly Neutralizing B cells Are Selected to Provide Defense against Pandemic Threat Influenza VirusesJenna J Guthmiller, Linda Yu-Ling Lan, Monica L Fernández-Quintero, et al.
Vaccine|January 5, 2025
Anti-neuraminidase and anti-hemagglutinin stalk responses to different influenza a(H7N9) vaccine regimensHana M El Sahly, Evan J Anderson, Lisa A Jackson, et al.
Science Translational Medicine|December 18, 2024
An influenza mRNA vaccine protects ferrets from lethal infection with highly pathogenic avian influenza A(H5N1) virusMasato Hatta, Yasuko Hatta, Angela Choi, et al.
Pageof 11